You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 18, 2024

TRINTELLIX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Trintellix, and when can generic versions of Trintellix launch?

Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixteen patent family members in forty-two countries.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.

DrugPatentWatch® Generic Entry Outlook for Trintellix

Trintellix was eligible for patent challenges on September 30, 2017.

There have been twenty-four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (vortioxetine hydrobromide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for TRINTELLIX
Drug Prices for TRINTELLIX

See drug prices for TRINTELLIX

Drug Sales Revenue Trends for TRINTELLIX

See drug sales revenues for TRINTELLIX

Recent Clinical Trials for TRINTELLIX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Seasons Biotechnology (Taizhou) Co., Ltd.Phase 1
H. Lundbeck A/SPhase 3
Todd DoylePhase 4

See all TRINTELLIX clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TRINTELLIX
Paragraph IV (Patent) Challenges for TRINTELLIX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRINTELLIX Tablets vortioxetine hydrobromide 5 mg, 10 mg, 15 mg and 20 mg 204447 15 2017-10-02

US Patents and Regulatory Information for TRINTELLIX

TRINTELLIX is protected by ten US patents and three FDA Regulatory Exclusivities.

Patents protecting TRINTELLIX

1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Therapeutic uses of compounds having combined SERT, 5-HT.sub.3 and 5-HT.sub.1A activity
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting TRINTELLIX

ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
Exclusivity Expiration: ⤷  Try a Trial

INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
Exclusivity Expiration: ⤷  Try a Trial

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRINTELLIX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TRINTELLIX

When does loss-of-exclusivity occur for TRINTELLIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1481
Estimated Expiration: ⤷  Try a Trial

Patent: 5797
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 07260355
Patent: 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Estimated Expiration: ⤷  Try a Trial

Patent: 08228638
Estimated Expiration: ⤷  Try a Trial

Austria

Patent: 95745
Estimated Expiration: ⤷  Try a Trial

Patent: 40941
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0713425
Estimated Expiration: ⤷  Try a Trial

Patent: 0808941
Estimated Expiration: ⤷  Try a Trial

Patent: 2020011899
Estimated Expiration: ⤷  Try a Trial

Patent: 2020011920
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 55212
Patent: 1-[2-(2, 4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE COMME COMPOSE PRESENTANT UNE ACTIVITE SUR LA SEROTONINE, 5-HT3 ET 5-HT1A POUR LE TRAITEMENT DU DEFICIT COGNITIF (1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT)
Estimated Expiration: ⤷  Try a Trial

Patent: 84571
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 08000795
Estimated Expiration: ⤷  Try a Trial

Patent: 11001610
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1472906
Patent: 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Estimated Expiration: ⤷  Try a Trial

Patent: 1636161
Patent: 1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to
Estimated Expiration: ⤷  Try a Trial

Patent: 2614179
Patent: 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
Estimated Expiration: ⤷  Try a Trial

Patent: 2617513
Patent: 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 AND 5-HT1A activity for the treatment of cognitive impairment
Estimated Expiration: ⤷  Try a Trial

Patent: 3948597
Patent: 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine used for treatment of pain or depression residual symptoms related with sleep and cognition
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 20962
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0110058
Estimated Expiration: ⤷  Try a Trial

Patent: 0120173
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 11183
Estimated Expiration: ⤷  Try a Trial

Patent: 12635
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 44043
Estimated Expiration: ⤷  Try a Trial

Patent: 42193
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 5287
Patent: 1-[2-(2,4-ДИМЕТИЛФЕНИЛСУЛЬФАНИЛ)ФЕНИЛ]ПИПЕРАЗИН В КАЧЕСТВЕ СОЕДИНЕНИЯ С СОЧЕТАНИЕМ АКТИВНОСТИ В ОТНОШЕНИИ ПОВТОРНОГО ЗАХВАТА СЕРОТОНИНА, 5-НТИ 5-НТДЛЯ ЛЕЧЕНИЯ КОГНИТИВНОГО НАРУШЕНИЯ (1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HTAND 5-HTACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT)
Estimated Expiration: ⤷  Try a Trial

Patent: 7058
Estimated Expiration: ⤷  Try a Trial

Patent: 0970018
Patent: 1-[2-(2,4-ДИМЕТИЛФЕНИЛСУЛЬФАНИЛ)ФЕНИЛ]ПИПЕРАЗИН В КАЧЕСТВЕ СОЕДИНЕНИЯ С СОЧЕТАНИЕМ АКТИВНОСТИ В ОТНОШЕНИИ ПОВТОРНОГО ЗАХВАТА СЕРОТОНИНА, 5-НТ3 И 5-НТ1А ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНОГО НАРУШЕНИЯ
Estimated Expiration: ⤷  Try a Trial

Patent: 0970870
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 44043
Patent: 1-[2-(2, 4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE COMME COMPOSE PRESENTANT UNE ACTIVITE SUR LA SEROTONINE, 5-HT3 ET 5-HT1A POUR LE TRAITEMENT DU DEFICIT COGNITIF (1- Ý[- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT)
Estimated Expiration: ⤷  Try a Trial

Patent: 42193
Patent: 1-[2-(2,4-DIMÉTHYLPHÉNYLSULFANYL)PHÉNYL]PIPÉRAZINE EN TANT QUE COMPOSÉ AVEC ACTIVITÉ COMBINÉ DU RECAPTAGE DE LA SEROTONINE, 5-HT3 ET 5-HT1A POUR LE TRAITEMENT DE LA DOLEUR OU DE SYMPTÔMES RÉSIDUELLES EN DEPRESSION CONCERNANT LE SOMMEIL ET LA COGNITION (1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION)
Estimated Expiration: ⤷  Try a Trial

Patent: 39201
Estimated Expiration: ⤷  Try a Trial

Finland

Patent: 44043
Estimated Expiration: ⤷  Try a Trial

Germany

Patent: 2008004643
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 34483
Patent: 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Patent: 71951
Estimated Expiration: ⤷  Try a Trial

Patent: 72014
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 5511
Patent: 1- [2-(2, 4-דימתילפנילסולפניל)-פניל]פיפרזין כתרכובת גבישית ושימושו להכנת תרופה לטיפול בליקוי קוגניטיבי (1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine which compound is crystalline and use thereof for the preparation of a medicament for treatment of cognitive impairment)
Estimated Expiration: ⤷  Try a Trial

Patent: 0956
Patent: 1-[2-(2,4-דימתילפנילסולפניל)-פניל]פיפרזין לטיפול בכאב (1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for use in the treatment of pain)
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 90013
Estimated Expiration: ⤷  Try a Trial

Patent: 71790
Estimated Expiration: ⤷  Try a Trial

Patent: 02929
Estimated Expiration: ⤷  Try a Trial

Patent: 63609
Estimated Expiration: ⤷  Try a Trial

Patent: 01742
Estimated Expiration: ⤷  Try a Trial

Patent: 24082
Estimated Expiration: ⤷  Try a Trial

Patent: 79035
Estimated Expiration: ⤷  Try a Trial

Patent: 09541216
Estimated Expiration: ⤷  Try a Trial

Patent: 10090165
Patent: 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Patent: 10521501
Estimated Expiration: ⤷  Try a Trial

Patent: 13056933
Patent: 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Patent: 15157872
Estimated Expiration: ⤷  Try a Trial

Patent: 17008086
Estimated Expiration: ⤷  Try a Trial

Patent: 18199689
Estimated Expiration: ⤷  Try a Trial

Patent: 20152732
Estimated Expiration: ⤷  Try a Trial

Patent: 23009175
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 0448
Patent: 1- [2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION
Estimated Expiration: ⤷  Try a Trial

Patent: 0647
Patent: 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 08016141
Patent: 1-[2-(2,4-DIMETILFENILSULFANIL)-FENIL] PIPERAZINA COMO UN COMPUESTO CON ACTIVIDAD COMBINADA DE RECAPTACIÓN DE SEROTONINA, 5-HT3 Y 5-HT1A.PARA EL TRATAMIENTO DE DAÑO COGNITIVO. (1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT.)
Estimated Expiration: ⤷  Try a Trial

Patent: 09009672
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 575
Patent: 1-[2-(2, 4-DIMÉTHYLPHÉNYLSULFANYL)-PHÉNYL]PIPÉRAZINE COMME COMPOSÉ PRÉSENTANT UNE ACTIVITÉ SUR LA SÉROTONINE, 5-HT3 ET 5-HT1A POUR LE TRAITEMENT DU DÉFICIT COGNITIF
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 2986
Patent: 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Patent: 9721
Patent: 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 3929
Estimated Expiration: ⤷  Try a Trial

Patent: 090229
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 44043
Estimated Expiration: ⤷  Try a Trial

Patent: 42193
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 44043
Estimated Expiration: ⤷  Try a Trial

Patent: 42193
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 560
Patent: 1-[2-(2,4-DIMETILFENILSULFANIL)FENIL]PIPERAZIN KAO JEDINJENJE SA KOMBINOVANOM AKTIVNOŠĆU VEZANOM ZA PONOVNO PREUZIMANJE SEROTONINA I 5-HT3 I 5HT1A AKTIVNOŠĆU, ZA LEČENJE BOLA ILI REZIDUALNIH SIMPTOMA U DEPRESIJI VEZANIH ZA SAN I KOGNICIJU (1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION)
Estimated Expiration: ⤷  Try a Trial

Patent: 205
Patent: 1-[2-(2,4-DIMETILFENILSULFANIL)-FENIL]PIPERAZIN KAO JEDINJENJE SA KOMBINOVANOM AKTIVNOŠĆU PONOVNOG UZIMANJA SEROTONINA, 5-HT3 I 5-HT1A, ZA TRETMAN KOGNITIVNIH OŠTEĆENJA (1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT)
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 44043
Estimated Expiration: ⤷  Try a Trial

Patent: 42193
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0810017
Patent: 1- [2- (2, 4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin Reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1445514
Estimated Expiration: ⤷  Try a Trial

Patent: 1459168
Estimated Expiration: ⤷  Try a Trial

Patent: 1627901
Estimated Expiration: ⤷  Try a Trial

Patent: 090028712
Patent: 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Patent: 090125251
Patent: 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION
Estimated Expiration: ⤷  Try a Trial

Patent: 130079619
Patent: 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Patent: 130133078
Patent: 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 55434
Estimated Expiration: ⤷  Try a Trial

Patent: 79200
Estimated Expiration: ⤷  Try a Trial

Patent: 32102
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 43091
Estimated Expiration: ⤷  Try a Trial

Patent: 0817340
Estimated Expiration: ⤷  Try a Trial

Patent: 0848411
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 08460
Patent: 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 250
Estimated Expiration: ⤷  Try a Trial

Patent: 392
Patent: 1-[2-(2,4-ДИМЕТИЛФЕНИЛСУЛЬФАНИЛ)ФЕНИЛ]ПИПЕРАЗИН КАК СОЕДИНЕНИЕ С КОМБИНИРОВАННОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ОБРАТНОГО ЗАХВАТА СЕРОТОНИНА, 5-НТ3 И 5-НТ1A ДЛЯ ЛЕЧЕНИЯ БОЛИ;1-[2-(2,4-ДИМЕТИЛФЕНІЛСУЛЬФАНІЛ)ФЕНІЛ]ПІПЕРАЗИН ЯК СПОЛУКА З КОМБІНОВАНОЮ АКТИВНІСТЮ СТОСОВНО ЗВОРОТНОГО ЗАХОПЛЕННЯ СЕРОТОНІНУ, 5-HT3 ТА 5-HT1A ДЛЯ ЛІКУВАННЯ БОЛЮ (1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN)
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRINTELLIX around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1171951 作為用於治療認知損傷的、具有結合的對血清素再吸收、 活性的化合物的 -二甲基苯基硫烷基 -苯基 哌嗪 (1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT 5-HT3 5-HT1A 1-[2-(24-)-]) ⤷  Try a Trial
Serbia 51560 1-[2-(2,4-DIMETILFENILSULFANIL)FENIL]PIPERAZIN KAO JEDINJENJE SA KOMBINOVANOM AKTIVNOŠĆU VEZANOM ZA PONOVNO PREUZIMANJE SEROTONINA I 5-HT3 I 5HT1A AKTIVNOŠĆU, ZA LEČENJE BOLA ILI REZIDUALNIH SIMPTOMA U DEPRESIJI VEZANIH ZA SAN I KOGNICIJU (1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION) ⤷  Try a Trial
South Korea 20130133078 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT ⤷  Try a Trial
Chile 2008000795 USO DE 1-[2-(2,4-DIMETILFENILSULFANIL)FENIL)PIPERAZINA PARA EL TRATAMIENTO DEL DOLOR O DE LOS SINTOMAS RESIDUALES DE LA DEPRESION; Y DICHO COMPUESTO. ⤷  Try a Trial
Japan 2010090165 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR TREATMENT OF COGNITIVE IMPAIRMENT ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TRINTELLIX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1436271 132014902248131 Italy ⤷  Try a Trial PRODUCT NAME: VORTIOXETINA O UN SUO SALE DI ADDIZIONE CON UN ACIDO FARMACEUTICAMENTE ACCETTABILE(BRINTELLIX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/891/001-2-3-4-5-6-7, 20131218
1436271 2014C/036 Belgium ⤷  Try a Trial PRODUCT NAME: VORTIOXETINE; AUTHORISATION NUMBER AND DATE: EU/1/13/891 20131220
1436271 PA2014013 Lithuania ⤷  Try a Trial PRODUCT NAME: VORTIOXETINUM; REGISTRATION NO/DATE: EU/1/13/891 20131218
1436271 CR 2014 00030 Denmark ⤷  Try a Trial PRODUCT NAME: VORTIOXETIN ELLER FARMACEUTISK ACCEPTABLE SYREADDITIONSSALTE DERAF, HERUNDER VORTIOXETINHYDROBROMID; REG. NO/DATE: EU/1/13/891 20131218
1436271 C300652 Netherlands ⤷  Try a Trial PRODUCT NAME: VORTIOXETINE OF EEN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.